Scholarlink

Background <p>Early debridement and grafting improve burn outcomes but pose significant blood loss risks. Tranexamic acid (TXA), an antifibrinolytic agent, reduces hemorrhage without increasing Venous thromboembolism (VTE) risk. While widely used in other surgeries, its role in burn surgery remains unclear. This meta-analysis evaluates TXA’s efficacy in improving surgical outcomes in burn patients.</p> Methods <p>We searched PubMed, Scopus, Web of Science, Cochrane, and Springer databases (last search: February 2025). Eligible RCTs compared TXA vs. placebo in burn surgery. Primary outcomes included blood loss (ml), transfusion need, hemoglobin change (g/dL), and hematocrit change (%). We conducted sensitivity, cumulative, and meta-regression analysis for all outcomes and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) for primary outcomes.</p> Results <p>We included five studies containing 227 patients. TXA significantly reduced operative blood loss (MD: -181.52 mL; <i>p</i> = 0.00; moderate certainty; I² = 61.46%) and transfusion need (RR: 0.52; <i>p</i> = 0.01; moderate certainty; I² = 0%). However, TXA did not significantly affect changes in hemoglobin (MD: 0.06; <i>p</i> = 0.94; low certainty; I² = 91.29%) or hematocrit levels (MD: 0.19; <i>p</i> = 0.90; very low certainty; I² = 88.94%).</p> Conclusion <p>TXA significantly reduces total operative blood loss and transfusion needs with moderate certainty. However, it does not significantly impact hemoglobin or hematocrit levels. Secondary outcomes showed no significant differences, including operative time, hospitalization length, and infection rates.</p> Trial registration <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Optimizing blood management in burn surgery: a meta-analysis of tranexamic acid vs. placebo

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月11日

查看全文
  • Mohamed Abdo Khalafallah,
  • Jana Ahmed Elsead,
  • Fatima Azzam Aboud,
  • Basmala Mohamed Koraim,
  • Islam Saeed Elhois

摘要

Background

Early debridement and grafting improve burn outcomes but pose significant blood loss risks. Tranexamic acid (TXA), an antifibrinolytic agent, reduces hemorrhage without increasing Venous thromboembolism (VTE) risk. While widely used in other surgeries, its role in burn surgery remains unclear. This meta-analysis evaluates TXA’s efficacy in improving surgical outcomes in burn patients.

Methods

We searched PubMed, Scopus, Web of Science, Cochrane, and Springer databases (last search: February 2025). Eligible RCTs compared TXA vs. placebo in burn surgery. Primary outcomes included blood loss (ml), transfusion need, hemoglobin change (g/dL), and hematocrit change (%). We conducted sensitivity, cumulative, and meta-regression analysis for all outcomes and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) for primary outcomes.

Results

We included five studies containing 227 patients. TXA significantly reduced operative blood loss (MD: -181.52 mL; p = 0.00; moderate certainty; I² = 61.46%) and transfusion need (RR: 0.52; p = 0.01; moderate certainty; I² = 0%). However, TXA did not significantly affect changes in hemoglobin (MD: 0.06; p = 0.94; low certainty; I² = 91.29%) or hematocrit levels (MD: 0.19; p = 0.90; very low certainty; I² = 88.94%).

Conclusion

TXA significantly reduces total operative blood loss and transfusion needs with moderate certainty. However, it does not significantly impact hemoglobin or hematocrit levels. Secondary outcomes showed no significant differences, including operative time, hospitalization length, and infection rates.

Trial registration

Not applicable.